Premium
THE CD19/CD3 BISPECIFIC ANTIBODY WORK EFFECTIVELY AS ADJUNCT WITH IBRUTINIB ON THE TREATMENT OF B‐CELL LYMPHOMA
Author(s) -
Yu H.,
Liu W.,
Mi L.,
Shu S.,
Zhang W.,
Ying Z.,
Chen H.,
Yan X.,
Shen W.,
Tu G.,
Ye Y.,
Li M.,
Wang D.,
Hu D.,
Cao J.,
Qi F.,
Wang X.,
Song Y.,
Zhu J.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.77_2881
Subject(s) - blinatumomab , bruton's tyrosine kinase , cd19 , cancer research , raji cell , ibrutinib , antibody , cd3 , il 2 receptor , t cell , chemistry , cytokine , medicine , cd8 , pharmacology , immunology , tyrosine kinase , immune system , leukemia , chronic lymphocytic leukemia , receptor